On Eve Of Plavix Trial, Apotex Suffers Another Blow

Law360, New York (January 19, 2007, 12:00 AM EST) -- The U.S. Court of Appeals for the Federal Circuit has once again handed a setback to Apotex Inc. in its Plavix patent spat with Sanofi-Aventis and Bristol-Myers Squibb Co., denying the Canadian drug maker’s petition to reconsider a ruling that barred it from selling a generic version of the blockbuster blood-thinner.

The Federal Circuit on Friday turned down a petition to rehear a ruling it handed down on Dec. 8 that prevents Apotex from selling its low-cost version of the drug in the United States....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.